Lyell Immunopharma, Inc. (LYEL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
201 Haskins Way
South San Francisco, CA 94080
United States of America (the)
Phone
650 695 0677
Website
Sector
Healthcare
Industry
Biotechnology
Employees
300
First IPO Date
June 17, 2021
| Name | Title | Pay | Year Born |
| Lynn Seely | Principal Executive Officer, President, CEO & Director | 1.13M | 1959 |
| Richard D. Klausner | Founder & Executive Chairman | 85,000 | 1952 |
| Gary Lee | Chief Scientific Officer | 786,805 | 1977 |
| Stephen J. Hill | Chief Operating Officer | 830,564 | 1971 |
| Mark A. Meltz | General Counsel & Corporate Secretary | 0 | 1974 |
| Jarrad Aguirre | Senior Vice President of Medical Affairs | 0 | N/A |
| Bryan Selby | Senior Vice President of Clinical Development Operations | 0 | N/A |
| Smital Shah | Principal Financial Officer, CFO & Chief Business Officer | 0 | 1976 |
| Veronica Sanchez Bulis | VP, Corporate Controller, Principal Accounting Officer | 0 | 1978 |
| Nellie Dillery | Director of Accounting | 0 | N/A |
| Ann Tomlin | Chief Human Resources Officer | 0 | N/A |
| Crystal L. Mackall | Founder & Scientific Advisor | 0 | 1961 |
| Stanley R. Riddell | Founder & Scientific Advisor | 0 | N/A |
Lyell Immunopharma, Inc. (LYEL) is a firm specializing in T cell reprogramming, dedicated to crafting T cell therapies for individuals battling solid tumors. The company's therapeutic innovation relies on advanced technology platforms: Gen-R, an ex vivo genetic reprogramming technique engineered to counteract T cell exhaustion, and Epi-R, an ex vivo epigenetic reprogramming method designed to cultivate T cells with sustained stem-like properties. Its development pipeline features notable candidates such as LYL797, a T cell product aimed at non-small cell lung cancer and triple-negative breast cancers; LYL845, intended for a broad range of solid tumors; and NY-ESO-1, focusing on synovial sarcoma and other specific solid tumor conditions. Additionally, Lyell holds a research and development collaboration and licensing agreement with GlaxoSmithKline for the NY-ESO-1 initiative. Founded in 2018, the company's main office is situated in South San Francisco, California.